Synonym
MDC-22; MDC22; MDC 22;
IUPAC/Chemical Name
2,3-bis((diethoxyphosphoryl)oxy)propyl 2-acetoxybenzoate
InChi Key
UISLTGPOZYGIOG-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H32O12P2/c1-6-26-33(23,27-7-2)30-15-17(32-34(24,28-8-3)29-9-4)14-25-20(22)18-12-10-11-13-19(18)31-16(5)21/h10-13,17H,6-9,14-15H2,1-5H3
SMILES Code
CC(OC1=C(C(OCC(OP(OCC)(OCC)=O)COP(OCC)(OCC)=O)=O)C=CC=C1)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
526.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Mattheolabakis G, Papayannis I, Yang J, Vaeth BM, Wang R, Bandovic J, Ouyang N, Rigas B, Mackenzie GG. Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice. Cancer Prev Res (Phila). 2016 Jul;9(7):624-34. doi: 10.1158/1940-6207.CAPR-15-0344. Epub 2016 May 2. PMID: 27138793; PMCID: PMC4930743.
2: Huang L, Wong CC, Cheng KW, Rigas B. Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect. PLoS One. 2014 Nov 4;9(11):e111720. doi: 10.1371/journal.pone.0111720. PMID: 25369051; PMCID: PMC4219766.
3: Huang L, Wong CC, Mackenzie GG, Sun Y, Cheng KW, Vrankova K, Alston N, Ouyang N, Rigas B. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. BMC Cancer. 2014 Feb 28;14:141. doi: 10.1186/1471-2407-14-141. PMID: 24575839; PMCID: PMC3941604.
4: Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, Rigas B. In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22). Pharm Res. 2012 Dec;29(12):3292-301. doi: 10.1007/s11095-012-0821-6. Epub 2012 Jul 11. PMID: 22782648; PMCID: PMC3602912.
5: Huang L, Mackenzie G, Ouyang N, Sun Y, Xie G, Johnson F, Komninou D, Rigas B. The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats. Br J Pharmacol. 2011 Apr;162(7):1521-33. doi: 10.1111/j.1476-5381.2010.01162.x. PMID: 21175575; PMCID: PMC3057290.
